NASA says Space Apps Challenge drew a record 181,835 registrations


The 14–15 November hackathon spanned 593 events worldwide, with registrations up 59% from 2025, NASA says. Projects will be judged before global winners are announced in January.
NASA says a record 181,835 people registered for its Space Apps Challenge held on 14–15 November 2026, across 593 events worldwide. Registrations rose 59% from the previous year, marking the fifth consecutive year of increased participation, the agency said in its November 17 announcement.
The previous edition in 2025 had 114,094 registrants from 167 countries and territories across 551 local events. The new figure counts people who registered, rather than the projects they submitted.
At locally organized, volunteer-led events, teams worked on one of 14 challenges in space exploration or Earth science using NASA’s open data. The challenges also used data from 17 international space agency partners. Agencies from Angola, Brazil and Argentina helped write challenges.
NASA welcomed people of all ages and experience levels; participants did not need to be programmers. Registration was open by 15 October.
For comparison, NASA said more than 11,500 projects were submitted in 2025. Its announcement of the latest registration record did not give a total for projects submitted in 2026.
Local judges select projects as global nominees, and expert judges then choose finalists. A committee of NASA and partner agency leaders selects the winners from those finalists. NASA says the 10 global winners will be announced in January.

The rocket delivered iQPS’s YAMATSUMI-II radar satellite to low Earth orbit from New Zealand. The Japanese company plans to collect its first observation data after calibration.
2 min

Daniel Whalen’s team proposes that black holes left by collapsing supermassive primordial stars power the compact red objects; the model is not an observational identification.
3 min

The agency says foreign regulators can use its assessments when considering medicines for sale. The program began with a tentative approval for the HIV medicine lenacapavir.
3 min